Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in Systemic Sclerosis
NCT04045743Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in systemic sclerosis (SSc), sponsored by Hellenic Institute for the Study of Sepsis. Started Jul 2019; status: completed.
02
Drugs
bermekimab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04045743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045743.